Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers
International Journal of Molecular Sciences · 19.01.2023 · 24 (3) · 1973
DOI: 10.3390/ijms24031973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.01.2023. Verfasst von Ghofraan Abdulsalam Atallah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Grant Scheme by the Ministry of Higher Education Malaysia.
Abstract (Originalsprache)
Ovarian cancer is a lethal reproductive tumour affecting women worldwide. The advancement in presentation and occurrence of chemoresistance are the key factors for poor survival among ovarian cancer women. Surgical debulking was the mainstay of systemic treatment for ovarian cancer, which was followed by a successful start to platinum-based chemotherapy. However, most women develop platinum resistance and relapse within six months of receiving first-line treatment. Thus, there is a great need to identify biomarkers to predict platinum resistance before enrolment into chemotherapy, which would facilitate individualized targeted therapy for these subgroups of patients to ensure better survival and an improved quality of life and overall outcome. Harnessing the immune response through immunotherapy approaches has changed the treatment way for patients with cancer. The immune outline has emerged as a beneficial tool for recognizing predictive and prognostic biomarkers clinically. Studying the tumour microenvironment (TME) of ovarian cancer tissue may provide awareness of actionable targets for enhancing chemotherapy outcomes and quality of life. This review analyses the relevance of immunohistochemistry biomarkers as prognostic biomarkers in predicting chemotherapy resistance and improving the quality of life in ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
- Department of Physiology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
- Department of Pathology, Faculty of Medicine, University Kebangsaan Malaysia, Bandar Tun Razak 56000, Kuala Lumpur, Malaysia.
ORCID-Profile: Nirmala Chandralega Kampan, Kah Teik Chew, Norfilza Mohd Mokhtar, Mohamad Nasir Bin Shafiee
Förderung
- Fundamental Research Grant Scheme by the Ministry of Higher Education Malaysia
Zitieren
APA
Atallah, G. A., Kampan, N. C., Chew, K. T., Mohd Mokhtar, N., Md Zin, R. R., Shafiee, M. N. B., & Abd Aziz, N. H. B. (2023). Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers. International Journal of Molecular Sciences, 24(3), 1973. https://doi.org/10.3390/ijms24031973
Vancouver
Atallah GA, Kampan NC, Chew KT, Mohd Mokhtar N, Md Zin RR, Shafiee MNB, et al. Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers. International Journal of Molecular Sciences. 2023;24(3):1973. doi:10.3390/ijms24031973
BibTeX
@article{Atallah2023,
author = {Atallah, Ghofraan Abdulsalam and Kampan, Nirmala Chandralega and Chew, Kah Teik and Mohd Mokhtar, Norfilza and Md Zin, Reena Rahayu and Shafiee, Mohamad Nasir Bin and Abd Aziz, Nor Haslinda Binti},
title = {Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {3},
pages = {1973},
doi = {10.3390/ijms24031973}
}
EUVIMED